Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1658 1675 1676
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17848736 | STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18644750 | CYCLIC CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RESIDUES | Non-Final OA | Ohio State Innovation Foundation |
| 17675910 | PEPTIDES FOR THE TREATMENT OF RENAL DISORDERS | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18534086 | SYNTHETIC DNA BINDING DOMAIN PEPTIDES AND USES THEREOF | Non-Final OA | The University of Chicago |
| 17778138 | PENTAPEPTIDE AND METHODS OF USE THEREOF | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 19020677 | PHARMACEUTICAL COMPOSITIONS FOR IMAGING, DIAGNOSIS AND TREATMENT OF CANCER | Final Rejection | Jubilant Draximage Inc. |
| 18257237 | DIPHENHYDRAMINE AND LACTOFERRIN FOR PREVENTION AND TREATMENT OF COVID-19 | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18903801 | REGENERATIVE PEPTIDES AND METHODS FOR USE THEREOF | Final Rejection | Animate Biosciences, Inc. |
| 17996917 | LIPID-PEPTIDE FUSION INHIBITORS AS SARS-COV-2 ANTIVIRALS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17828609 | Mitochondria-Targeted Polypeptide, Preparation Method thereof, and Use thereof | Non-Final OA | SUN YAT-SEN UNIVERSITY |
| 18633283 | N-Terminal Capping Modules of Ankyrin Repeat Domains | Non-Final OA | Athebio AG |
| 18008771 | DOCK TAG SYSTEM | Final Rejection | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18433336 | METHODS FOR TREATING MYELIN ASSOCIATED DISEASES AND MITOCHONDRIA ASSOCIATED DISEASES | Final Rejection | Larimar Therapeutics, Inc. |
| 18018518 | BROAD-SPECTRUM ANTIVIRAL DRUG FOR ENTEROVIRUS, AND APPLICATION | Final Rejection | WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES |
| 18316988 | TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF | Final Rejection | Takeda Pharmaceutical Company Limited |
| 17264720 | FORMULATIONS FOR IMPROVED STABILITY OF RECOMBINANT HUMAN PARATHYROID HORMONE | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 17642505 | IMAGING AND THERAPEUTIC COMPOSITIONS | Final Rejection | The University of Melbourne |
| 18031416 | LINEAR APELIN RECEPTOR AGONISTS | Non-Final OA | NXERA PHARMA UK LIMITED |
| 18370941 | COMPOSITIONS AND METHODS FOR IMPROVING VACCINE THERAPY | Non-Final OA | Lile Method Research, LLC |
| 17839323 | TOPICAL CYCLOSPORINE FOR TREATING PSORIASIS AND OTHER AILMENTS | Non-Final OA | Dyve Biosciences, Inc. |
| 18271407 | PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX | Non-Final OA | Jonathan David GARMAN |
| 17267652 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | Non-Final OA | LUBRIZOL ADVANCED MATERIALS, INC. |
| 18039130 | BIOLOGICALLY ACTIVE MATERIAL CONJUGATE HAVING BIOTIN MOIETY, FATTY ACID MOIETY, OR COMBINATION THEREOF COUPLED THERETO | Non-Final OA | D&D Pharmatech Inc. |
| 16759200 | Drug and Method for Treating Liver Diseases Related to Hepatitis B Viruses in Full-Dose Condition | Final Rejection | Shanghai Hep Pharmaceutical Co., Ltd. |
| 17714896 | ANIMAL-FREE DIETARY COLLAGEN | Non-Final OA | Geltor, Inc. |
| 18099258 | Calcium independent phosphatidylserine binding compounds for detecting phosphatidylserine positive cells | Non-Final OA | BIOLEGEND, INC. |
| 17767734 | IFIT Polypeptides and Uses for Treating Tuberculosis Infection | Non-Final OA | Stellenbosch University |
| 17981862 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION AND WOUND HEALING | Final Rejection | Alastin Skincare, Inc. |
| 17955923 | [161Tb]-BASED RADIOPEPTIDES | Final Rejection | Paul Scherrer Institute |
| 17802038 | Hair Growth and Scalp Preparations | Non-Final OA | Meng Teng LIM |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy